Miwa H, Kojima K, Ono F, Kobayashi T, Tsurumi T, Hatosaki A, Iijima T, Orita K
Jpn J Surg. 1983 Jan;13(1):20-4. doi: 10.1007/BF02469685.
Immunotherapy with levamisole (LMS) and combined splenectomy were performed in the cases of stages III and IV gastric cancer of the upper and middle stomach and associated with total gastrectomy. The cell-mediated immunity and the survival rates for both groups were compared with controls. Combined splenectomy was not effective for cases of stage III gastric cancer, but was effective for those in stage IV. Comparing the cumulative survival rates of the immunotherapy group with the controls, cases of stages III and IV gastric cancer without splenectomy, the survival rate of those with immunotherapy was higher than that of the control group in the cases of the stage III, but the result was reverse in cases of stage IV gastric cancer. Changes in the cell-mediated immunity correlated with the survival rates.
对胃中上段III期和IV期胃癌患者进行了左旋咪唑(LMS)免疫治疗并联合脾切除术,且均行全胃切除术。将两组的细胞介导免疫和生存率与对照组进行比较。联合脾切除术对III期胃癌患者无效,但对IV期患者有效。将未行脾切除术的III期和IV期胃癌免疫治疗组的累积生存率与对照组进行比较,III期患者中免疫治疗组的生存率高于对照组,但IV期胃癌患者的结果相反。细胞介导免疫的变化与生存率相关。